US teens who received recommended vaccines at public healthcare centers in 2020 were less likely to initiate and complete the human papillomavirus (HPV) vaccine series than those at private facilities, finds a study published yesterday in JAMA Pediatrics.
Led by researchers at the Henry Ford Health System, the study also found that teens at public centers had lower odds of receiving a clinician recommendation for the vaccine.
The team sampled data from the 2020 National Immunization Survey–Teen on 20,162 patients aged 13 to 17 years. Initiation was defined as receipt of at least one dose of HPV vaccine, and completion was considered at least two or three doses.
About 31,000 HPV-related cancers are diagnosed annually in the United States. "The HPV vaccine can prevent more than 90% of these cancers, yet national uptake remains lower than the Healthy People 2030 target of 80% completion," the authors wrote.
Importance of public healthcare centers
A total of 81.4% of teens received a recommendation for the vaccine, while 75.1% started and 58.6% completed the series. Public-facility patients were 38% less likely to receive a clinician recommendation than those at private centers (aOR, 0.62).
Public health centers play a crucial role in serving minority communities and in mitigating racial and ethnic disparities in health care.
HPV vaccine initiation differed significantly between public (71%) and private (77%) facilities, as did series completion (50% vs 61%, respectively). In adjusted analyses, teens at public centers had 29% lower chances of starting (adjusted odds ratio [aOR], 0.71) and 38% lower odds of completing (aOR, 0.62) the series than those at private facilities.
"Public health centers play a crucial role in serving minority communities and in mitigating racial and ethnic disparities in health care," the researchers said. "Urgent actions are needed to enhance clinician participation in the promotion of HPV vaccination, especially in public facilities," they concluded.
The Advisory Committee on Immunization Practices recommends the HPV vaccine for adolescents aged 11 to 12 years and catch-up vaccination for those 13 to 26.